TipRanks
55% OFF
PC:NAN6Z

NanoPhoria Bioscience

NanoPhoria Bioscience is a Milan-based biotech company specializing in the development of a nano-in-micro and lung-to-heart delivery platform utilizing inorganic calcium phosphate nanoparticles. The company's lead product, NP-MP1, is a first-in-class peptide designed to target cardiac L-type calcium channels, aiming to improve ejection fraction in patients with heart failure with reduced ejection fraction (HFrEF). NanoPhoria's innovative platform seeks to address unmet medical needs by enhancing cardiac contractility and offering new treatment paradigms for cardiovascular and other chronic diseases.

Leadership & Board

Latest Estimated Valuation

Estimated Valuation
―
Total Amount Raised
$84M
Total Funding Rounds
1
Latest Funding Amount
$84M
Latest Funding Round
Series A
Post-Money Valuation
―

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Oct 08, 2025Series A$83.50M―

Investors

Investor NameFunding Round
Sofinnova PartnersSeries A
Panakès PartnersSeries A
XGEN VentureSeries A
CDP Venture CapitalSeries A

Similar Companies

A snapshot of private companies similar to NanoPhoria Bioscience, helping you discover and navigate related company profiles.

Related News and Analysis